Atish Choudhury, MD PhD

NCCN awards funding to 4 advanced prostate cancer research projects The research projects are assessing combination therapies in advanced prostate cancer that include the use of relugolix.

Thank you to NCCN, Sumitomo Pharma, Pfizer Oncology, and Bayer Oncology for supporting CLEARED (Comeback from Long CoursE ADT with RElugolix and Darolutamide). www.urologytimes.com/view/nccn-aw...

Now activated! CLEARED will enroll pts with high-risk localized, lymph node-positive or low volume HSPC (planned for treatment interruption) to receive 2 years of relugolix+darolutamide for PK studies of the combo and to assess T recovery after completion. clinicaltrials.gov/study/NCT064...

BellissiMo's Mo Space Movember, the month formerly known as November, is a moustache growing charity event held during November each year that raises funds and awareness for men's health.

It's not too late to join our contribute to our team at movember.com/t/bellissimo to support Movember's efforts towards prostate cancer, testicular cancer and mental health research and resources.

See you at Kings Back Bay on Monday 11/25/24 from 6-10 pm for BellissiMO’s Movember Fundraising Finale. There will be food, karaoke, and celebration!

On multivariable analysis, duration of treatment >=12 months was independently associated with cPFS after T recovery, provocatively suggesting that prolonged systemic therapy could sterilize (or render permanently dormant) micrometastatic disease and lead to "cure" in a subset.

Of note, 3-year cPFS after T recovery for patients receiving "total therapy" was 51% for those who received >=12 mo ADT, and the swimmer's plot shows patients out to > 10 years after T recovery.

Combined Fixed-duration Systemic Treatment and Metastasis-directed Radiotherapy for Oligometastatic Hormone-sensitive Prostate Cancer It is unclear whether “total therapy” (androgen deprivation therapy [ADT] with or without an androgen receptor pathway inhibitor [ARPI], metastasis-di…

Can oligometastatic prostate cancer be cured with "total therapy" including radiation to all sites of disease and hormonal therapy? Dr. Praful Ravi and I along with colleagues at Dana-Farber present data from our cohort. www.sciencedirect.com/science/arti...